Abstract 1740P
Background
About 55% of the population worldwide lives in urban areas, and agreeing to WHO (World Health Organization), 91% of people in cities do not breathe safe air. There is evidence of a positive correlation between PM2.5 and lung cancer mortality. The Metropolitan Area of Monterrey, México, is the country's third most significant and most polluted, with an annual average of 23 μg/m3 PM2.5, equivalent to 2.3 times the value established by the WHO. Objective. This study aimed to identify if spatial exposure patterns to PM2.5 correlate to respiratory tract cancer incidence.
Methods
Daily concentrations of PM2.5 were estimated considering the PM10/PM2.5 ratio in local stations that measured both fractions. Subsequently, the available fraction per station was calculated, considering the fractions of all available station data. Finally, the general fraction of the entire study period was calculated. The morbidity data for this study came from an individual-level database that contained the geographical coordinates of the residences of the airway cancer cases (bronchi, lung, larynx, and paranasal sinuses).
Results
The average concentration of PM2.5 was 32.4 μg/m3, 3.24 times the limit established by the WHO. We identified that the increase in PM levels was associated with the number of cancer cases. The mean age of the cases was 70 years. There were 76.77% (n = 476) patients with a lung cancer diagnosis, followed by laryngeal cancer at 21.77% (n = 135). Interestingly, we detect that 44.35% (n = 275) has never smoked. On the other hand, there were 44.67% (n=277) heavy smokers in the cancer cases.
Conclusions
Implementing preventive measures to reduce emissions and exposure to PM2.5 and other air pollutants in polluted cities is necessary. High concentrations of PM2.5 are related to cancer cases, and it is essential to implement preventive cancer detection measures in polluted areas, not only in smokers’ cases. In addition, spatial analyses are valuable to describe, quantify and explain the geographical variations of diseases associated with particulate matter exposure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centro Universitario Contra el Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23